Intensive Bevacizumab Boosts Vision in Macular Degeneration

Eyestem completes phase 1 trial of retinal cell therapy with promising vision gains - Pharmafile

Eyestem Research has announced the successful completion of its phase 1 trial evaluating Eyecyte-RPE, an investigational cell therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The company has submitted its clinical study report to India’s Central Drugs Standard Control Organisation (CDSCO) and is preparing to launch phase 2 pending regulatory approval. […] The post Eyestem completes phase 1 trial of ret…

Retina specialist Dr. Lloyd Clark joins Annexon - BioTuesdays

Annexon (NASDAQ: ANNX) announced the appointment of Lloyd Clark, MD, as SVP, ophthalmology strategy and innovation. Dr. Clark brings more than 25 years of experience in treating retinal diseases and advancing novel therapies, having served as a principal investigator in more than 70 clinical trials. A pioneer in the development of VEGF inhibitors, he has also served for the past decade as assistant clinical professor of ophthalmology at the Univ…

#Adverums ARTEMIS Phase 3 Study Pioneering a Future in Gene Therapy for Wet AMD,

'Innovative Advances in Gene Therapy: Adverum Biotechnologies Initiates Pivotal ARTEMIS Phase 3 Study for Wet AMD' Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a pioneer in the field of gene therapy, has taken a significant step forward in the management of wet age-related macular degeneration (AMD) with the initiation of its ARTEMIS Phase 3 study. This groundbreaking trial aims to assess the efficacy and safety of Ixo-vec (ixoberogene soroparv…

Intensive Bevacizumab Boosts Vision in Macular Degeneration

Early and intensive treatment of age-related macular degeneration with bevacizumab is associated with greater long-term improvements in visual acuity than are ranibizumab or aflibercept, a real-world study from the Netherlands shows.

25-Year Retina Expert Joins Annexon: Key Hire Could Accelerate Vision-Preserving AMD Drug Development

Veteran retina specialist Dr. Lloyd Clark brings expertise from 70 clinical trials to advance ANX007, showing unprecedented vision preservation in GA patients. Learn timeline.

Rethinking end points in AMD: the power of OCT imaging with Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS

Optical coherence tomography markers—like the ellipsoid zone—are reshaping clinical trials in intermediate age-related macular degeneration, as highlighted at the 2025 International SPECTRALIS Symposium — And Beyond (ISS).